

Unigene Laboratories

[View the current Unigene Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10448-Unigene+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/10448-Unigene+Laboratories.html>)

Contact Details:

110 Little Falls Road

Fairfield

NJ

07004

United States of America

Tel: (973)882-0860

Fax: (973)882-8277

Email: jgilligan@unigene.com

Unigene Laboratories, Inc. is a biopharmaceutical company engaged in the research, production and delivery of valuable therapeutic peptide hormones. The Company has patented manufacturing technology for producing amidated peptides cost-effectively and in quantities sufficient to support the worldwide commercialization of peptide therapeutics for oral delivery. The Company has also patented novel oral drug delivery technology for peptide hormones. Unigene's first commercial products will be different formulations of calcitonin for the treatment of osteoporosis and other indications. The Company has launched its injectable calcitonin product in the European Union and is developing a nasal calcitonin product, as well as oral formulations of calcitonin and other peptides.

Recent Publications by Unigene Laboratories:



- [Calcitonin for osteoporosis and bone pain.](#)

Calcitonin has been approved for the treatment of osteoporosis and other... 3rd February, 2004
Unigene Laboratories Inc., 110 Little Falls Road, Fairfield, New Jersey- Curr Pharm Des. 2003;9(32):2659-76.

- [Production of salmon calcitonin by direct expression of a glycine-extended precursor in Escherichia coli.](#)

The export of heterologous products into the conditioned medium of an... 9th May, 2003
Unigene Laboratories, Inc., 110 Little Falls Road, Fairfield, NJ 07004,- Protein Expr Purif. 2002 Nov;26(2):249-59.

Press Releases on Unigene Laboratories:

Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www
Reportlinker Adds Laboratory Filtration Equipment - Global Market Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Laboratory Filtration Equipment - Global Market Trends http://www
Reportlinker Adds Wound Care Products - A World Market Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Wound Care Products - A World Market Analysis http://www.reportlinker.com
Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www
Reportlinker Adds Probiotics - A Global Update of Market Trends & Opportunities	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Probiotics - A Global Update of Market Trends & Opportunities http://

BioNews Results for Unigene Laboratories



- [StockProfiler.US: Stock Watch: UGNE, PNRC, TGLN](#)
Individual.com: Nov 10 2009 6:14PM Matching: unigene laboratories
- [Unigene Announces Financial Results for Third Quarter 2009](#)
Freshnews.com: Nov 9 2009 10:23PM Matching: unigene laboratories
- [Unigene Announces Financial Results for Third Quarter 2009](#)
Genetic Engineering News: Nov 9 2009 10:34PM Matching: unigene laboratories
- [Thewallstreetleader.com: HearAtLast Holdings, Inc. & Unigene Laboratories, Inc.](#)
Individual.com: Nov 5 2009 11:58PM Matching: unigene laboratories
- [Unigene to Release Third Quarter 2009 Results and Host Conference Call](#)
Individual.com: Nov 5 2009 7:34AM Matching: unigene laboratories
- [StockProfiler.US: Stock Watch: UGNE, NHPR, SOAN](#)
Individual.com: Nov 5 2009 7:33AM Matching: unigene laboratories

- [Unigene to Release Third Quarter 2009 Results and Host Conference Call](#)
Yahoo! Canada: Nov 4 2009 1:18PM Matching: unigene laboratories
- [Tarsa, Zelos advance drugs to treat osteoporosis patients](#)
Biz Journals: Nov 2 2009 6:16AM Matching: unigene laboratories
- [Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics](#)
Pharma Live: Oct 21 2009 11:35PM Matching: unigene laboratories
- [Stocks That Stand Out For Oct. 21th, 2009 Are MPPC, CCTR, AEMD, NXTH, UGNE](#)
Pharmacy Choice: Oct 22 2009 3:05AM Matching: unigene laboratories
- [Unigene Hands Tarsa Phase III Asset as \\$24M Series A Closes](#)
Therapeutics Daily: Oct 21 2009 7:16AM Matching: unigene laboratories
- [Unigene Laboratories, Inc. \(UGNE\) Licenses Phase III Oral Calcitonin Program to New Company, Tarsa Therapeutic](#)
BioSpace: Oct 21 2009 3:26AM Matching: unigene laboratories
- [Unigene to Host Conference Call to Discuss Phase III Oral Calcitonin Licensing Agreement with Tarsa Therapeutics](#)
Yahoo! Canada: Oct 20 2009 8:08PM Matching: unigene laboratories
- [Unigene to Host Conference Call to Discuss Phase III Oral Calcitonin Licensing Agreement with Tarsa Therapeuti](#)
Genetic Engineering News: Oct 20 2009 8:21PM Matching: unigene laboratories
- [Unigene to Host Conference Call to Discuss Phase III Oral Calcitonin Licensing Agreement with Tarsa Therapeutics](#)
SmartBrief: Oct 20 2009 8:14PM Matching: unigene laboratories

Unigene Laboratories Clinical Trials:



- [A Dose Selection Study of Oral Recombinant Salmon Calcitonin \(rsCT\) in Normal, Healthy, Postmenopausal Women](#)

Unigene Laboratories Patents:



- 7553655- [Bacterial host cell for the direct expression of peptides](#)
- 4708934- [.alpha.-amidation enzyme](#)
- 5789234- [Expression systems for amidating enzyme](#)
- 5912014- [Oral salmon calcitonin pharmaceutical products](#)
- 6086918- [Oral peptide pharmaceutical products](#)
- 6103495- [Direct expression of peptides into culture media](#)
- 6210925- [Direct expression of peptides into culture media](#)

- 6319685- [Alpha-amidating enzyme compositions and processes for their production and use](#)
- 6440392- [Nasal calcitonin formulations](#)
- 6627438- [Direct expression of peptides into culture media](#)
- 6673574- [Oral delivery of peptides using enzyme-cleavable membrane translocators](#)
- 6737250- [Direct expression of peptides into culture media](#)
- 7316819- [Oral peptide pharmaceutical dosage form and method of production](#)
- 7445911- [Enzymatic reactions in the presence of keto acids](#)
- 7531518- [Method for fostering bone formation and preservation](#)
- 7541174- [Bacterial host cell for the direct expression of peptides](#)
- 4689220- [Immunization by immunogenic implant](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

